Clinical Trials Logo

Type 2 Hepatorenal Syndrome clinical trials

View clinical trials related to Type 2 Hepatorenal Syndrome.

Filter by:
  • None
  • Page 1

NCT ID: NCT00240045 Completed - Refractory Ascites Clinical Trials

The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

Start date: October 2005
Phase: Phase 2/Phase 3
Study type: Interventional

We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are mediated in part by diminished circulatory volume and that treatment with midodrine, octreotide and albumin can improve renal and patient outcomes by restoring effective circulating volume and systemic perfusion. Our primary objective is to assess change in creatinine clearance using inulin. We will enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR, albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before, during, and after initiation of drug and compared.